Is Magnesium Stress Randomized Trial safe?

The current Migaku evidence database contains 2 reusable source documents for Magnesium Stress Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - This review synthesizes current evidence and provides context for an ongoing cluster-randomized trial that is testing whether a center-wide dialysate magnesium concentration of 0.75 mmol/L, versus ≤0.50 mmol/L, delivered as a policy and sustained for up to four years, reduces the risk of major cardiovascular-related hospitalizations. [Tannar B (2026); evidence level 4] - Systematic reviews and meta-analyses show that hypomagnesemia is associated with higher risks of cardiovascular events and all-cause mortality in hemodialysis. [Tannar B (2026); evidence level 4] - Given encouraging but predominantly surrogate-based evidence, adequately powered randomized trials are warranted. [Tannar B (2026); evidence level 4] - Purpose of review Cardiovascular disease (CVD) accounts for nearly half of deaths among people receiving maintenance hemodialysis. [Tannar B (2026); evidence level 4] - Although Mg is frequently discussed as an analgesic supplement, emerging evidence suggests that it acts as a neurovascular-metabolic modulator. [Yoon Y (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.